JP2022526856A - 臨床的に意義のあるegfr変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体(car)を含む、組成物および方法 - Google Patents
臨床的に意義のあるegfr変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体(car)を含む、組成物および方法 Download PDFInfo
- Publication number
- JP2022526856A JP2022526856A JP2021560665A JP2021560665A JP2022526856A JP 2022526856 A JP2022526856 A JP 2022526856A JP 2021560665 A JP2021560665 A JP 2021560665A JP 2021560665 A JP2021560665 A JP 2021560665A JP 2022526856 A JP2022526856 A JP 2022526856A
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- seq
- cells
- car
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 220
- 238000000034 method Methods 0.000 title claims abstract description 106
- 239000000203 mixture Substances 0.000 title abstract description 30
- 230000009260 cross reactivity Effects 0.000 title abstract description 5
- 108010021466 Mutant Proteins Proteins 0.000 title abstract description 4
- 102000008300 Mutant Proteins Human genes 0.000 title abstract description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 title abstract description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 title abstract 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 claims description 356
- 102000001301 EGF receptor Human genes 0.000 claims description 346
- 108060006698 EGF receptor Proteins 0.000 claims description 346
- 230000027455 binding Effects 0.000 claims description 205
- 239000000427 antigen Substances 0.000 claims description 178
- 102000036639 antigens Human genes 0.000 claims description 178
- 108091007433 antigens Proteins 0.000 claims description 177
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 119
- 150000007523 nucleic acids Chemical class 0.000 claims description 108
- 206010028980 Neoplasm Diseases 0.000 claims description 104
- 230000003834 intracellular effect Effects 0.000 claims description 101
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 98
- 108010043610 KIR Receptors Proteins 0.000 claims description 79
- 102000002698 KIR Receptors Human genes 0.000 claims description 74
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 73
- 102000039446 nucleic acids Human genes 0.000 claims description 73
- 108020004707 nucleic acids Proteins 0.000 claims description 73
- 125000003729 nucleotide group Chemical group 0.000 claims description 60
- 239000002773 nucleotide Substances 0.000 claims description 59
- 108010029485 Protein Isoforms Proteins 0.000 claims description 57
- 102000001708 Protein Isoforms Human genes 0.000 claims description 57
- 238000011282 treatment Methods 0.000 claims description 57
- 201000011510 cancer Diseases 0.000 claims description 39
- 239000013598 vector Substances 0.000 claims description 33
- 239000012634 fragment Substances 0.000 claims description 27
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 17
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 16
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 16
- 230000005746 immune checkpoint blockade Effects 0.000 claims description 16
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 13
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 13
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 12
- 210000004881 tumor cell Anatomy 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 8
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 7
- 210000002220 organoid Anatomy 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 5
- 239000000833 heterodimer Substances 0.000 claims description 5
- 230000003389 potentiating effect Effects 0.000 claims description 5
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 4
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 4
- 238000001574 biopsy Methods 0.000 claims description 4
- 239000000710 homodimer Substances 0.000 claims description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 3
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 3
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 3
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 230000030833 cell death Effects 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 96
- 208000005017 glioblastoma Diseases 0.000 description 65
- 108090000765 processed proteins & peptides Proteins 0.000 description 54
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 50
- 102000004169 proteins and genes Human genes 0.000 description 48
- 235000018102 proteins Nutrition 0.000 description 47
- 108091028043 Nucleic acid sequence Proteins 0.000 description 45
- 235000001014 amino acid Nutrition 0.000 description 45
- 230000014509 gene expression Effects 0.000 description 45
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 41
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 41
- 229940024606 amino acid Drugs 0.000 description 41
- 150000001413 amino acids Chemical class 0.000 description 41
- 102000004196 processed proteins & peptides Human genes 0.000 description 39
- 230000004068 intracellular signaling Effects 0.000 description 37
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 33
- 229920001184 polypeptide Polymers 0.000 description 32
- 238000000338 in vitro Methods 0.000 description 28
- 210000000822 natural killer cell Anatomy 0.000 description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 26
- 108060003951 Immunoglobulin Proteins 0.000 description 26
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 26
- 102000018358 immunoglobulin Human genes 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 24
- 201000010099 disease Diseases 0.000 description 22
- 108091008874 T cell receptors Proteins 0.000 description 21
- 239000003446 ligand Substances 0.000 description 21
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 20
- 239000002609 medium Substances 0.000 description 20
- 230000035772 mutation Effects 0.000 description 20
- 108091033319 polynucleotide Proteins 0.000 description 20
- 102000040430 polynucleotide Human genes 0.000 description 20
- 239000002157 polynucleotide Substances 0.000 description 20
- 102000005962 receptors Human genes 0.000 description 20
- 108020003175 receptors Proteins 0.000 description 20
- 238000003752 polymerase chain reaction Methods 0.000 description 19
- 230000006870 function Effects 0.000 description 18
- 230000035897 transcription Effects 0.000 description 18
- 238000013518 transcription Methods 0.000 description 18
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 17
- 238000004520 electroporation Methods 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 17
- 230000011664 signaling Effects 0.000 description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 16
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 16
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 230000004913 activation Effects 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 108020003589 5' Untranslated Regions Proteins 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- -1 10-100 amino acids Chemical class 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 12
- 108020005345 3' Untranslated Regions Proteins 0.000 description 11
- 241000713666 Lentivirus Species 0.000 description 11
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 230000009870 specific binding Effects 0.000 description 11
- 230000004936 stimulating effect Effects 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 10
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000001461 cytolytic effect Effects 0.000 description 10
- 230000001086 cytosolic effect Effects 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 102100035932 Cocaine- and amphetamine-regulated transcript protein Human genes 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- 101000715592 Homo sapiens Cocaine- and amphetamine-regulated transcript protein Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 125000006850 spacer group Chemical group 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 8
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 7
- 108010052199 HLA-C Antigens Proteins 0.000 description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 7
- 102000043129 MHC class I family Human genes 0.000 description 7
- 108091054437 MHC class I family Proteins 0.000 description 7
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 7
- 102000015636 Oligopeptides Human genes 0.000 description 7
- 108010038807 Oligopeptides Proteins 0.000 description 7
- 108091036407 Polyadenylation Proteins 0.000 description 7
- 102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000002659 cell therapy Methods 0.000 description 7
- 229910052804 chromium Inorganic materials 0.000 description 7
- 239000011651 chromium Substances 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 230000002018 overexpression Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 239000004474 valine Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 6
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 108010052285 Membrane Proteins Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 102100035891 T-cell surface glycoprotein CD3 delta chain Human genes 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 230000008499 blood brain barrier function Effects 0.000 description 6
- 210000001218 blood-brain barrier Anatomy 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 210000005220 cytoplasmic tail Anatomy 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000003248 secreting effect Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 101150039808 Egfr gene Proteins 0.000 description 5
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 5
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 5
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 description 5
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 210000001130 astrocyte Anatomy 0.000 description 5
- 230000003416 augmentation Effects 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000000139 costimulatory effect Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000002601 intratumoral effect Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229960003301 nivolumab Drugs 0.000 description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 description 4
- 102100027207 CD27 antigen Human genes 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 108091033380 Coding strand Proteins 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 4
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 4
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 4
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 4
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 4
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 4
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 4
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 4
- 102100037911 T-cell surface glycoprotein CD3 gamma chain Human genes 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 238000002617 apheresis Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000006037 cell lysis Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 229960005395 cetuximab Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000004186 co-expression Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000005917 in vivo anti-tumor Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000002101 lytic effect Effects 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 229960002621 pembrolizumab Drugs 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- OXURYBANZVUSFY-UHFFFAOYSA-N 2-[3-(diaminomethylideneamino)propyl]butanedioic acid Chemical compound NC(N)=NCCCC(C(O)=O)CC(O)=O OXURYBANZVUSFY-UHFFFAOYSA-N 0.000 description 3
- 102000006306 Antigen Receptors Human genes 0.000 description 3
- 108010083359 Antigen Receptors Proteins 0.000 description 3
- 102100024263 CD160 antigen Human genes 0.000 description 3
- 102100038078 CD276 antigen Human genes 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 102100035793 CD83 antigen Human genes 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 description 3
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 3
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 3
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 description 3
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 description 3
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 description 3
- 101000945339 Homo sapiens Killer cell immunoglobulin-like receptor 2DS2 Proteins 0.000 description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 3
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 description 3
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 description 3
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 3
- 101000946863 Homo sapiens T-cell surface glycoprotein CD3 delta chain Proteins 0.000 description 3
- 101000738335 Homo sapiens T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 description 3
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 3
- 102000009438 IgE Receptors Human genes 0.000 description 3
- 108010073816 IgE Receptors Proteins 0.000 description 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 3
- 102100032818 Integrin alpha-4 Human genes 0.000 description 3
- 102100032816 Integrin alpha-6 Human genes 0.000 description 3
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 3
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 description 3
- 102100033630 Killer cell immunoglobulin-like receptor 2DS2 Human genes 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 3
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 3
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 3
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 238000003559 RNA-seq method Methods 0.000 description 3
- 102100029197 SLAM family member 6 Human genes 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 3
- 101710146340 T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 3
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 3
- 108010060889 Toll-like receptor 1 Proteins 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 229950009791 durvalumab Drugs 0.000 description 3
- 108700021358 erbB-1 Genes Proteins 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000011519 second-line treatment Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000004500 stellate cell Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 101710145634 Antigen 1 Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 2
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 2
- 101710095183 B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 102100038077 CD226 antigen Human genes 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 2
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 2
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 2
- 101100112778 Homo sapiens CD247 gene Proteins 0.000 description 2
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 2
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 2
- 101000945333 Homo sapiens Killer cell immunoglobulin-like receptor 2DL3 Proteins 0.000 description 2
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 description 2
- 101000945490 Homo sapiens Killer cell immunoglobulin-like receptor 3DL2 Proteins 0.000 description 2
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 description 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 2
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 2
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100025323 Integrin alpha-1 Human genes 0.000 description 2
- 102100022341 Integrin alpha-E Human genes 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 2
- 102100033634 Killer cell immunoglobulin-like receptor 2DL3 Human genes 0.000 description 2
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 2
- 102100034840 Killer cell immunoglobulin-like receptor 3DL2 Human genes 0.000 description 2
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 239000012270 PD-1 inhibitor Substances 0.000 description 2
- 239000012668 PD-1-inhibitor Substances 0.000 description 2
- 101710124239 Poly(A) polymerase Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 102100027744 Semaphorin-4D Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108050005496 T-cell surface glycoprotein CD3 delta chains Proteins 0.000 description 2
- 101710131569 T-cell surface glycoprotein CD3 gamma chain Proteins 0.000 description 2
- 101710156660 T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 description 2
- 101710187864 TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 2
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000013626 chemical specie Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000012595 freezing medium Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 description 2
- 108700026078 glutathione trisulfide Proteins 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108091008042 inhibitory receptors Proteins 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000012886 linear function Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 230000037230 mobility Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940121655 pd-1 inhibitor Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000005783 single-strand break Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002483 superagonistic effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000003151 transfection method Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- KUHSEZKIEJYEHN-BXRBKJIMSA-N (2s)-2-amino-3-hydroxypropanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.OC[C@H](N)C(O)=O KUHSEZKIEJYEHN-BXRBKJIMSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 101150029062 15 gene Proteins 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 102000002627 4-1BB Ligand Human genes 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- 108020005176 AU Rich Elements Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 108010056102 CD100 antigen Proteins 0.000 description 1
- 108010017009 CD11b Antigen Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 108010001445 CD79 Antigens Proteins 0.000 description 1
- 102000000796 CD79 Antigens Human genes 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 101710139831 CD82 antigen Proteins 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108091028732 Concatemer Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
- 108010021470 Fc gamma receptor IIC Proteins 0.000 description 1
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 description 1
- 101710120217 Fc receptor-like protein 5 Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 1
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 108010086377 HLA-A3 Antigen Proteins 0.000 description 1
- 108010002634 HLA-Bw4 antigen Proteins 0.000 description 1
- 108010016670 HLA-C*02 antigen Proteins 0.000 description 1
- 108010068567 HLA-Cw1 antigen Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 108010024164 HLA-G Antigens Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101100112772 Homo sapiens CD3G gene Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 description 1
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 description 1
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101000945331 Homo sapiens Killer cell immunoglobulin-like receptor 2DL4 Proteins 0.000 description 1
- 101000945337 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5A Proteins 0.000 description 1
- 101000945335 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5B Proteins 0.000 description 1
- 101000945340 Homo sapiens Killer cell immunoglobulin-like receptor 2DS1 Proteins 0.000 description 1
- 101000945343 Homo sapiens Killer cell immunoglobulin-like receptor 2DS3 Proteins 0.000 description 1
- 101000945342 Homo sapiens Killer cell immunoglobulin-like receptor 2DS4 Proteins 0.000 description 1
- 101000945346 Homo sapiens Killer cell immunoglobulin-like receptor 2DS5 Proteins 0.000 description 1
- 101000945493 Homo sapiens Killer cell immunoglobulin-like receptor 3DL3 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 1
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 description 1
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 description 1
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 1
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 description 1
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 description 1
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 description 1
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 1
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 description 1
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 1
- 101000738413 Homo sapiens T-cell surface glycoprotein CD3 gamma chain Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 1
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 description 1
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100039904 Integrin alpha-D Human genes 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 108010030465 Integrin alpha6beta1 Proteins 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102100033016 Integrin beta-7 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 1
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 1
- 101150069255 KLRC1 gene Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100033633 Killer cell immunoglobulin-like receptor 2DL4 Human genes 0.000 description 1
- 102100033629 Killer cell immunoglobulin-like receptor 2DL5A Human genes 0.000 description 1
- 102100033628 Killer cell immunoglobulin-like receptor 2DL5B Human genes 0.000 description 1
- 102100033631 Killer cell immunoglobulin-like receptor 2DS1 Human genes 0.000 description 1
- 102100033625 Killer cell immunoglobulin-like receptor 2DS3 Human genes 0.000 description 1
- 102100033624 Killer cell immunoglobulin-like receptor 2DS4 Human genes 0.000 description 1
- 102100033626 Killer cell immunoglobulin-like receptor 2DS5 Human genes 0.000 description 1
- 102100034834 Killer cell immunoglobulin-like receptor 3DL3 Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 description 1
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 description 1
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029206 Low affinity immunoglobulin gamma Fc region receptor II-c Human genes 0.000 description 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101100118551 Mus musculus Egfr gene Proteins 0.000 description 1
- 101100181099 Mus musculus Klra1 gene Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- 108010001880 NK Cell Lectin-Like Receptor Subfamily C Proteins 0.000 description 1
- 102000000834 NK Cell Lectin-Like Receptor Subfamily C Human genes 0.000 description 1
- 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 description 1
- 102000000812 NK Cell Lectin-Like Receptor Subfamily K Human genes 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- 208000021320 Nasu-Hakola disease Diseases 0.000 description 1
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 description 1
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 102000015623 Polynucleotide Adenylyltransferase Human genes 0.000 description 1
- 108010024055 Polynucleotide adenylyltransferase Proteins 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 101800001295 Putative ATP-dependent helicase Proteins 0.000 description 1
- 101800001006 Putative helicase Proteins 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100029216 SLAM family member 5 Human genes 0.000 description 1
- 102100029198 SLAM family member 7 Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100036014 T-cell surface glycoprotein CD1c Human genes 0.000 description 1
- 101710085551 T-cell surface glycoprotein CD3 delta chain Proteins 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 description 1
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 208000029499 cancer-related condition Diseases 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 208000012191 childhood neoplasm Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 108091007930 cytoplasmic receptors Proteins 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 231100000050 cytotoxic potential Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BPHQZTVXXXJVHI-UHFFFAOYSA-N dimyristoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-UHFFFAOYSA-N 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 108010002591 epsilon receptor Proteins 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000045108 human EGFR Human genes 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 229940126546 immune checkpoint molecule Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940045426 kymriah Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000001216 nucleic acid method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 208000031334 polycystic lipomembranous osteodysplasia with sclerosing leukoencephaly Diseases 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000004492 positive regulation of T cell proliferation Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 102220003351 rs387906411 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 108010078373 tisagenlecleucel Proteins 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000013024 troubleshooting Methods 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
- 229940045208 yescarta Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
Description
本出願は、米国特許法第119条(e)の下、2019年4月12日付で出願された米国仮特許出願第62/833,456号および2019年8月27日付で出願された米国仮特許出願第62/892,343号への優先権を主張し、それらの出願の各々は、参照によりその全体が本明細書に組み入れられる。
膠芽腫(GBM)または神経膠腫グレードIVは、3.19人/100,000人/年の年間発生率(約10,000人)であり、標準治療の外科手術、放射線療法、および化学療法後に14.6ヶ月の生存期間中央値を有する、壊滅的ながんである。過去20年間に処置の進歩はほとんど実現されておらず、2年生存率は25%近くのままである。近年、低強度の交流電場がいくらかの潜在性を示したとはいえ、新規な処置の必要性は依然として大きい。
定義
特に定義されない限り、本明細書において用いられる科学用語および技術用語は、本発明が属する技術分野の当業者によって一般に理解されているものと同じ意味を有する。本明細書に記載されるものに類似する、またはそれと等価である任意の方法および材料を本発明の試験のための実施に使用することができるものの、好ましい材料および方法が本明細書に記載される。本発明を説明および請求するにあたり、以下の用語が使用される。
本発明は、臨床的に意義のあるEGFR変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体(CAR)およびその使用方法を提供する。ある特定の態様では、CARは、上皮増殖因子受容体(EGFR)の複数のアイソフォームに結合することが可能な抗原結合ドメインと、膜貫通ドメインと、細胞内シグナル伝達ドメインとを含む。ある特定の態様では、CARはヒト化CARである。ある特定の態様では、CARは親和性成熟されたヒト化CARである。ある特定の態様では、CARはKIR CARである。ある特定の局面では、本発明は、本発明のCARを投与することによる、それを必要とする対象におけるがんを処置する方法を含む。
本発明は、複数のEGFRアイソフォームに結合する/親和性を有することが可能なキメラ抗原受容体(CAR)を提供する。該CARをコードする核酸、該核酸をコードするベクター、および該CAR、ベクター、または核酸を含む改変された細胞(例えば、改変されたT細胞)も提供される。
CARの抗原結合ドメインは、タンパク質、糖質、および糖脂質を含む特異的標的抗原に結合するためのCARの細胞外領域である。いくつかの態様では、CARは、標的細胞(例えば、がん細胞)上の標的抗原(例えば腫瘍関連抗原)に対する親和性を含む。標的抗原は、標的細胞に関連する任意の種類のタンパク質またはそのエピトープを含み得る。例えば、CARは、標的細胞の特定の状態を示す、標的細胞上の標的抗原に対する親和性を含み得る。
によってコードされるアミノ酸配列GGGGSGGGGSGGGGS(SEQ ID NO:46)を有するリンカー配列によって隔てられている。ある特定の態様では、リンカーはSEQ ID NO:48のアミノ酸配列を含む。ある特定の態様では、リンカーは、SEQ ID NO:49の核酸配列によりコードされる。
膜貫通ドメインに関して、本発明のCAR(例えば、交差反応性EGFR CAR)は、抗原結合ドメインを細胞内ドメインと接続する膜貫通ドメインを含むよう設計され得る。対象のCARの膜貫通ドメインは、細胞(例えば、免疫細胞またはその前駆細胞)の形質膜を貫通することが可能な領域である。膜貫通ドメインは、細胞膜、例えば、真核生物細胞膜内への挿入のためのものである。いくつかの態様では、膜貫通ドメインは、CARの抗原結合ドメインと細胞内ドメインとの間に挟まれている。
(例えば、Glaser et al., J. Biol. Chem. (2005) 280:41494-41503を参照されたい);
などのうちの1つを含むことができる。
を含む;例えば、Yan et al., J. Biol. Chem. (2012) 287: 5891-5897を参照されたい。一態様では、ヒンジ領域は、ヒトCD8に由来するアミノ酸配列またはそのバリアントを含むことができる。
本発明の対象CARは、細胞内ドメインも含む。CARの細胞内ドメインは、CARが発現されている細胞(例えば、免疫細胞)のエフェクター機能の少なくとも1つの活性化を担う。細胞内ドメインは、エフェクター機能シグナルを伝達し、細胞(例えば、免疫細胞)が、その専門の機能、例えば、標的細胞を傷つけることおよび/または破壊することを果たすように方向づける。
ある特定の局面では、本発明は、ナチュラルキラー(NK)細胞上に見出される受容体の成分を含むCAR設計である「KIR-CAR」に関する。本明細書に提供されるKIR-CARは、上皮増殖因子受容体(EGFR)の複数のアイソフォームに結合することが可能な抗原結合ドメインと、KIR膜貫通ドメインおよび/またはKIR細胞内(細胞質)ドメインとを含む。
本発明の対象CARは、EFGRの複数のアイソフォーム(例えば、wtEGFR、変異型EGFR、EGFRA289V、EGFRA289D、EGFRA289T、EGFRR108K、EGFRR108G、およびEGFRG598V)に対して親和性を有するCARである。一態様では、本発明のEGFR CARは、SEQ ID NO:19に示される核酸配列によってコードされ得る、SEQ ID NO:20に示されるアミノ酸配列を含む。
本明細書に記載される改変された細胞(例えば、EGFRの複数のアイソフォームに結合することが可能なCARを含むT細胞)は、免疫療法のための組成物中に含まれる場合がある。組成物は、薬学的組成物を含む場合があり、薬学的に許容される担体をさらに含む場合がある。改変されたT細胞を含む薬学的組成物の治療有効量が投与される場合がある。
核酸を細胞内に導入する方法は、物理的、生物学的および化学的方法を含む。RNAなどのポリヌクレオチドを宿主細胞内に導入するための物理的方法は、リン酸カルシウム沈殿、リポフェクション、微粒子銃、微量注入、エレクトロポレーションなどを含む。RNAは、エレクトロポレーション(Amaxa Nucleofector-II (Amaxa Biosystems, Cologne, Germany))、(ECM 830 (BTX)(Harvard Instruments, Boston, Mass.)またはGene Pulser II(BioRad, Denver, Colo.)、Multiporator(Eppendorf, Hamburg Germany)を含む市販の方法を用いて標的細胞内に導入することができる。RNAは、リポフェクションを用いて、ポリマー封入を用いて、ペプチド媒介トランスフェクションを用いて、または「遺伝子銃」などのバイオリスティック粒子送達システムを用いて、細胞内に導入することもできる(例えば、Nishikawa, et al. Hum Gene Ther., 12(8):861-70 (2001)を参照されたい。
一態様では、宿主細胞中に導入される核酸はRNAである。別の態様では、RNAは、インビトロ転写されたRNAまたは合成RNAを含むmRNAである。RNAは、ポリメラーゼ連鎖反応(PCR)により生成された鋳型を使用するインビトロ転写によって産生される。任意の供給源からの関心対象のDNAを、PCRにより、適切なプライマーおよびRNAポリメラーゼを使用して、インビトロmRNA合成のための鋳型に直接変換することができる。DNAの供給源は、例えば、ゲノムDNA、プラスミドDNA、ファージDNA、cDNA、合成DNA配列または任意の他の適切なDNA供給源であり得る。インビトロ転写のための所望のテンプレートはキメラ膜タンパク質である。例としてテンプレートは、抗体、抗体の断片または抗体の一部分をコードする。別の例として、テンプレートは、抗CD3などの抗体の単鎖可変ドメインを含む細胞外ドメインと、共刺激分子の細胞内ドメインとを含む。一態様では、RNAキメラ膜タンパク質のためのテンプレートは、共刺激分子に対する抗体に由来する抗原結合ドメインを含む細胞外ドメインと、CD28および4-1BBの細胞内ドメインの一部分に由来する細胞内ドメインとを含むキメラ膜タンパク質をコードする。
ある特定の態様では、T細胞の供給源は対象から得られる。対象の非限定的な例は、ヒト、イヌ、ネコ、マウス、ラット、およびそれらのトランスジェニック種を含む。好ましくは、対象はヒトである。T細胞は、末梢血単核細胞、骨髄、リンパ節組織、脾臓組織、臍帯、および腫瘍を含むいくつかの供給源から得られることができる。ある特定の態様では、当技術分野において入手可能な任意の数のT細胞株が使用される場合がある。ある特定の態様では、T細胞は、当業者に公知の任意の数の技法、例えばフィコール分離を用いて対象から収集された血液のユニットから得られることができる。一態様では、個体の循環血由来の細胞は、アフェレーシスまたは白血球アフェレーシスによって得られる。アフェレーシス産物は、典型的にT細胞、単球、顆粒球、B細胞、他の有核白血球、赤血球、および血小板を含むリンパ球を含有する。アフェレーシスによって収集された細胞は、洗浄されて、血漿画分が除去され、細胞がリン酸緩衝食塩水(PBS)または洗浄溶液などの適切な緩衝液または培地中に入れられる場合があり、洗浄溶液は、その後の処理段階のためにカルシウムを欠如し、かつマグネシウムを欠如する場合またはすべての二価陽イオンでないにしろ多くを欠如する場合がある。洗浄後、細胞は、例えば、Ca不含、Mg不含PBSなどの多様な生体適合性緩衝液中に再懸濁される場合がある。あるいは、アフェレーシス試料の望ましくない成分が除去され、細胞が培地中に直接再懸濁される場合がある。
ある特例の態様において、本明細書に開示される改変された細胞は、約10倍、20倍、30倍、40倍、50倍、60倍、70倍、80倍、90倍、100倍、200倍、300倍、400倍、500倍、600倍、700倍、800倍、900倍、1000倍、2000倍、3000倍、4000倍、5000倍、6000倍、7000倍、8000倍、9000倍、10,000倍、100,000倍、1,000,000倍、10,000,000倍、またはそれ超、およびそれらの間の任意およびすべての整数(whole integer)および分数(partial integer)倍にすることができる。一態様では、T細胞は約20倍~約50倍の範囲で増大する。
本発明の薬学的組成物は、本明細書に記載のとおりの改変されたT細胞を、1つまたは複数の薬学的にまたは生理学的に許容される担体、希釈剤または賦形剤と組み合わせて含み得る。そのような組成物は、中性緩衝食塩水、リン酸緩衝食塩水などの緩衝液;グルコース、マンノース、スクロースまたはデキストラン、マンニトールなどの炭水化物;タンパク質;ポリペプチドまたはグリシンなどのアミノ酸;酸化防止剤;EDTAまたはグルタチオンなどのキレート剤;アジュバント(例えば、水酸化アルミニウム);および保存料を含み得る。本発明の組成物は、好ましくは、静脈内投与用に製剤化される。
これから以下の実施例を参照して本発明を説明する。これらの実施例は、例証だけの目的で提供されるものであって、本発明は、これらの実施例に限定されるわけではなく、本明細書において提供される教示の結果として明白であるすべての変形を包含する。
上皮増殖因子受容体(EGFR)(ErbB1)座位内の変化は、GBM中の最高頻度の遺伝子変化に相当する。GBMにおいて二重微小染色体としてのEGFR座位の限局した増幅によって媒介されるものなどのEGFRの過剰発現が長い間認識されており、症例の60%に見出される。EGFRの変異もまた頻度が高い。エクソン2~7を欠如する発がん性EGFRバリアント(EGFRvIII)は、GBMの約30%に見出される。GBM症例の次世代シーケンシングデータに加えてTCGAデータを使用して、発がん活性を有するミスセンス変異が、EGFR細胞外ドメイン(ECD)の位置108、289、および598に同定された(図7)。遡及的分析により、これらの変異を有する患者が全生存率の不良を示すことが示された。EGFRが増幅されたGBMの60%超はECDにおける変異を示し、これらの変異は、交差反応性CART細胞によって標的とされることができた。
本明細書において複数のEGFRアイソフォームに対して広い特異性を誘発するキメラ抗原受容体(CAR)T細胞を生成した。モノクローナル抗体mAb806由来のscFvと、CD8ヒンジドメインと、CD8膜貫通ドメインと、4-1BB細胞内シグナル伝達ドメインとをコードするレンチウイルス発現ベクターを構築した(図1A)。初代ヒトCD4+ T細胞およびCD8+ T細胞にCARをコードするレンチウイルスベクターを形質導入した。6日インキュベーション後、約60%のT細胞が細胞表面にEGFR特異的806-4-1BB CARを発現した(図1B)。
本明細書において複数のEGFRアイソフォームに対する広い特異性を誘発するKIR CARもまた生成した。806-scFv、KIR膜貫通および細胞内ドメイン、ならびにDAP12配列を含有するレンチウイルスベクターを構築した(図4A)。抗CD3/抗CD28 T細胞活性化ビーズで初代ヒトT細胞を24時間刺激した。次いで、T細胞に806-KIRレンチウイルスベクターを形質導入し、インビトロで10日間拡大増殖させた。ビオチン化ヤギ-抗マウスF(ab)2に続いてストレプトアビジン-APCを用いるフローサイトメトリーによって分析した場合、約44%のT細胞が806 KIR CARを発現した(図4B)。EGFR発現GBM細胞株ならびにそのバリアントvIII発現GBM細胞株およびA289V発現GBM細胞株に対する806-KIR CAR Tの抗原特異的細胞溶解活性を、生存細胞についてのレポーター遺伝子としてルシフェラーゼを用いて測定した(図5)。806 KIR CAR T細胞は、U87 MG、U87 MG EGFRvIII、U87 wtEGFR、U87 wtEGFR/EGFRvIII、およびU87 wtEGFR/EGFRA289V細胞株を溶解することができた。EGFRvIIIおよびEGFR野生型を認識するEGFRvIII特異的2173 CARおよびセツキシマブ(C225)CARを陽性対照として使用した。データにより、806 KIR CAR T細胞の抗原特異的細胞溶解活性が実証された。
ヒト化ABT806 scFvを4-1BBz CAR中にコードするレンチウイルス発現ベクターおよびヒト化ABT806 scFvをKIR-CAR中にコードする別のベクターを創出した。ヒト化配列はSEQ ID NO. 23~28に対応する。初代ヒトCD4+ T細胞およびCD8+ T細胞にベクターを形質導入し、6日のインキュベーション後に顕著な陽性を実証した。ヒト化モノクローナルABT806 4-1BBz CARおよびヒト化モノクローナルABT806 KIR CARは、どちらも、EGFR変異体を用いて改変されたU87 MG細胞株またはEGFR変異体を用いて改変されたU87 wtEGFR細胞株に対して細胞溶解活性を示した。
ヒト化806-41BBz CARを用いて皮下の動物組み合わせ実験を行い、抗PD-1阻害剤をU87 wtEGFR/EGFRvIIIに対して試験した(図16A~16B)。最も良い臨床効力を達成するために、複数の注入を用いて抗PD-1阻害およびCAR T細胞の両方の投与計画を比較する。806-41BB CAR T細胞の追加的な腫瘍成長阻害研究のために同所腫瘍モデルを使用する。806 41BBzおよび806 KIR CARの静脈内および髄腔内投与を用いて送達経路を比較する。
806 BBz CARと抗PD1 抗体との併用療法で皮下腫瘍を処置した(図16A~16B)。PBSまたは抗PD-1抗体のいずれかと非形質導入T細胞または806 BBz CAR T細胞との組み合わせで皮下U87 wtEGFR/EGFRvIII細胞株を処置した。併用療法によって、生物発光によって決定される場合の相対腫瘍変化に、より大きな減少が実証された(図16A)。CAR T注入の16日後のPBS + 非形質導入(UTD)細胞に対する腫瘍変化率を図16Bに示す。
GBMオルガノイド(GBO)をCAR T細胞と共培養した(図21A~21C)。GBOは、Jacob et al. (2019) Cell 180:1;188-204.e22に詳細に記載されており、その内容は、その全体で参照により本明細書に組み入れられる。簡潔には、GBOを以下の方法により生成した。
本明細書における変数の任意の定義における要素の一覧の詳述は、記載された要素の任意の単一の要素または組み合わせ(または小組み合わせ)としてのその変数の定義を含む。本明細書における態様の詳述は、任意の単一の態様としての態様または任意の他の態様もしくはその部分との組み合わせた態様を含む。
Claims (72)
- キメラ抗原受容体(CAR)をコードする単離された核酸分子であって、CARが、上皮増殖因子受容体(EGFR)の複数のアイソフォームに結合することが可能な抗原結合ドメインと、膜貫通ドメインと、細胞内ドメインとを含む、単離された核酸分子。
- EGFRアイソフォームが、野生型EGFR(wtEGFR)、変異型EGFR、EGFRA289V、EGFRA289D、EGFRA289T、EGFRR108K、EGFRR108G、EGFRG598V、EGFRD126Y、EGFRC628F、EGFRR108K/A289V、EGFRR108K/D126Y、EGFRA289V/G598V、EGFRA289V/C628F、およびEGFRバリアントIIからなる群より選択される、請求項1記載の単離された核酸。
- 抗原結合ドメインが、抗体、scFv、Fab、またはその任意の断片からなる群より選択される、請求項1記載の単離された核酸。
- 抗原結合ドメインが、SEQ ID NO:1、SEQ ID NO:31、SEQ ID NO:79、SEQ ID NO:81、SEQ ID NO:83、およびSEQ ID NO:85からなる群より選択されるヌクレオチド配列によってコードされる、請求項1記載の単離された核酸。
- 抗原結合ドメインが、SEQ ID NO:2、SEQ ID NO:32、SEQ ID NO:80、SEQ ID NO:82、SEQ ID NO:84、およびSEQ ID NO:86からなる群より選択されるアミノ酸配列を含む、請求項1記載の単離された核酸。
- 抗原結合ドメインが、SEQ ID NO:3、SEQ ID NO:27、およびSEQ ID NO:30からなる群より選択されるアミノ酸配列を含む軽鎖可変領域を含む、請求項1記載の単離された核酸。
- 抗原結合ドメインが、SEQ ID NO:4、SEQ ID NO:26、およびSEQ ID NO:29からなる群より選択されるアミノ酸配列を含む重鎖可変領域を含む、請求項1記載の単離された核酸。
- 抗原結合ドメインが、SEQ ID NO:5、6、および7からなる群より選択されるアミノ酸配列を含む軽鎖相補性決定領域(LCDR)を含む、請求項1記載の単離された核酸。
- 抗原結合ドメインが、SEQ ID NO:8、9、および10からなる群より選択されるアミノ酸配列を含む重鎖相補性決定領域(HCDR)を含む、請求項1記載の単離された核酸。
- CARが、ヒンジ領域をさらに含む、請求項1記載の単離された核酸。
- ヒンジ領域が、SEQ ID NO:11またはSEQ ID NO:71のヌクレオチド配列によってコードされる、請求項10記載の単離された核酸。
- 膜貫通ドメインが、SEQ ID NO:12またはSEQ ID NO:73のヌクレオチド配列によってコードされる、請求項1記載の単離された核酸。
- 細胞内ドメインが、SEQ ID NO:13またはSEQ ID NO:75のヌクレオチド配列によってコードされる、請求項1記載の単離された核酸。
- 細胞内ドメインが、SEQ ID NO:14またはSEQ ID NO:77を含むヌクレオチド配列によってコードされる、請求項1記載の単離された核酸。
- 細胞内ドメインが、SEQ ID NO:13およびSEQ ID NO:14を含むヌクレオチド配列またはSEQ ID NO:75およびSEQ ID NO:77を含むヌクレオチド配列によってコードされる、請求項1記載の単離された核酸。
- CARが、SEQ ID NO:21、64、66、または68からなる群より選択されるヌクレオチド配列によってコードされる、請求項1記載の単離された核酸。
- 膜貫通ドメインおよび/または細胞内ドメインが、キラー細胞免疫グロブリン様受容体(KIR)を含む、請求項1記載の単離された核酸。
- DAP12をコードする核酸をさらに含む、請求項17記載の単離された核酸。
- CARが、SEQ ID NO:22、65、67、および69からなる群より選択されるアミノ酸配列を含む、請求項1記載の単離された核酸。
- CARが、EGFRホモ二量体、EGFRヘテロ二量体、EGFRオリゴマー、および/またはEGFR/ErbBオリゴマーに結合することが可能である、請求項1記載の単離された核酸。
- 前記請求項のいずれか一項記載の単離された核酸を含む、ベクター。
- 交差反応性キメラ抗原受容体(CAR)を含む改変された細胞であって、CARが、EGFRの複数のアイソフォームに結合することが可能な抗原結合ドメインと、膜貫通ドメインと、細胞内ドメインとを含む、改変された細胞。
- EGFRアイソフォームが、野生型EGFR(wtEGFR)、変異型EGFR、EGFRA289V、EGFRA289D、EGFRA289T、EGFRR108K、EGFRR108G、EGFRG598V、EGFRD126Y、EGFRC628F、EGFRR108K/A289V、EGFRR108K/D126Y、EGFRA289V/G598V、EGFRA289V/C628F、およびEGFRバリアントIIからなる群より選択される、請求項22記載の改変された細胞。
- 抗原結合ドメインが、抗体、scFv、Fab、またはその任意の断片からなる群より選択される、請求項22記載の改変された細胞。
- 抗原結合ドメインが、SEQ ID NO:1、SEQ ID NO:31、SEQ ID NO:79、SEQ ID NO:81、SEQ ID NO:83、およびSEQ ID NO:85からなる群より選択されるヌクレオチド配列によってコードされる、請求項22記載の改変された細胞。
- 抗原結合ドメインが、SEQ ID NO:2、SEQ ID NO:32、SEQ ID NO:80、SEQ ID NO:82、SEQ ID NO:84、およびSEQ ID NO:86からなる群より選択されるアミノ酸配列を含む、請求項22記載の改変された細胞。
- 抗原結合ドメインが、SEQ ID NO:3、SEQ ID NO:27、およびSEQ ID NO:30からなる群より選択されるアミノ酸配列を含む軽鎖可変領域を含む、請求項22記載の改変された細胞。
- 抗原結合ドメインが、SEQ ID NO:4、SEQ ID NO:26、およびSEQ ID NO:29からなる群より選択されるアミノ酸配列を含む重鎖可変領域を含む、請求項22記載の改変された細胞。
- 抗原結合ドメインが、SEQ ID NO:5、6、および7からなる群より選択されるアミノ酸配列を含む軽鎖相補性決定領域(LCDR)を含む、請求項22記載の改変された細胞。
- 抗原結合ドメインが、SEQ ID NO:8、9、および10からなる群より選択されるアミノ酸配列を含む重鎖相補性決定領域(HCDR)を含む、請求項22記載の改変された細胞。
- CARが、ヒンジ領域をさらに含む、請求項22記載の改変された細胞。
- ヒンジ領域が、SEQ ID NO:72のアミノ酸配列を含む、請求項31記載の改変された細胞。
- 膜貫通ドメインが、SEQ ID NO:74のアミノ酸配列を含む、請求項22記載の改変された細胞。
- 細胞内ドメインが、SEQ ID NO:76のアミノ酸配列を含む、請求項22記載の改変された細胞。
- 細胞内ドメインが、SEQ ID NO:78のアミノ酸配列を含む、請求項22記載の改変された細胞。
- 細胞内ドメインが、SEQ ID NO:76およびSEQ ID NO:78のアミノ酸配列を含む、請求項22記載の改変された細胞。
- CARが、SEQ ID NO:21、64、66、または68からなる群より選択されるヌクレオチド配列によってコードされる、請求項22記載の改変された細胞。
- 膜貫通ドメインおよび/または細胞内ドメインが、キラー細胞免疫グロブリン様受容体(KIR)を含む、請求項22記載の改変された細胞。
- DAP12をコードする核酸をさらに含む、請求項38記載の改変された細胞。
- CARが、SEQ ID NO:22、65、67、および69からなる群より選択されるアミノ酸配列を含む、請求項22記載の改変された細胞。
- CARが、EGFRホモ二量体、EGFRヘテロ二量体、EGFRオリゴマー、および/またはEGFR/ErbBオリゴマーに結合することが可能である、請求項22記載の改変された細胞。
- T細胞である、請求項22記載の改変された細胞。
- 自己細胞である、請求項22記載の改変された細胞。
- ヒト細胞である、請求項22記載の改変された細胞。
- 請求項22~44のいずれか一項記載の改変された細胞を対象に投与する段階を含む、それを必要とする対象におけるがんを処置するための方法。
- CARを含む改変された細胞を対象に投与する段階を含む、それを必要とする対象におけるがんを処置するための方法であって、
CARが、EGFRの複数のアイソフォームに結合することが可能な抗原結合ドメインと、膜貫通ドメインと、細胞内ドメインとを含む、
方法。 - EGFRアイソフォームが、野生型EGFR(wtEGFR)、変異型EGFR、EGFRA289V、EGFRA289D、EGFRA289T、EGFRR108K、EGFRR108G、EGFRG598V、EGFRD126Y、EGFRC628F、EGFRR108K/A289V、EGFRR108K/D126Y、EGFRA289V/G598V、EGFRA289V/C628F、およびEGFRバリアントIIからなる群より選択される、請求項46記載の方法。
- 抗原結合ドメインが、SEQ ID NO:1、SEQ ID NO:31、SEQ ID NO:79、SEQ ID NO:81、SEQ ID NO:83、およびSEQ ID NO:85からなる群より選択されるヌクレオチド配列によってコードされる、請求項46記載の方法。
- 抗原結合ドメインが、SEQ ID NO:2、SEQ ID NO:32、SEQ ID NO:80、SEQ ID NO:82、SEQ ID NO:84、およびSEQ ID NO:86からなる群より選択されるアミノ酸配列を含む、請求項46記載の方法。
- 抗原結合ドメインが、SEQ ID NO:3、SEQ ID NO:27、およびSEQ ID NO:30からなる群より選択されるアミノ酸配列を含む軽鎖可変領域を含む、請求項46記載の方法。
- 抗原結合ドメインが、SEQ ID NO:4、SEQ ID NO:26、およびSEQ ID NO:29からなる群より選択されるアミノ酸配列を含む重鎖可変領域を含む、請求項46記載の方法。
- 抗原結合ドメインが、SEQ ID NO:5、6、および7からなる群より選択されるアミノ酸配列を含む軽鎖相補性決定領域(LCDR)を含む、請求項46記載の方法。
- 抗原結合ドメインが、SEQ ID NO:8、9、および10からなる群より選択されるアミノ酸配列を含む重鎖相補性決定領域(HCDR)を含む、請求項46記載の方法。
- CARが、SEQ ID NO:21、64、66、または68からなる群より選択されるヌクレオチド配列によってコードされる、請求項46記載の方法。
- CARが、SEQ ID NO:22、65、67、および69からなる群より選択されるアミノ酸配列を含む、請求項46記載の方法。
- 追加的な処置を対象に施す段階をさらに含む、請求項45~55のいずれか一項記載の方法。
- 追加的な処置が、免疫チェックポイント阻害(ICB)を含む、請求項56記載の方法。
- ICBが、抗PD-1処置、抗PD-L1処置、抗TIM3処置、および抗CTLA-4処置からなる群より選択される、請求項57記載の方法。
- 処置が局所的に送達される、請求項45~58のいずれか一項記載の方法。
- 改変された細胞が、ミニボディーをさらに含む、請求項45または46記載の方法。
- ミニボディーが、PD-1に特異的なscFvとヒトIgG CH3ドメインとを含む、請求項60記載の方法。
- ミニボディーが、CTLA-4に特異的なscFvとヒトIgG CH3ドメインとを含む、請求項60記載の方法。
- ミニボディーが、TIM-3に特異的なscFvとヒトIgG CH3ドメインとを含む、請求項60記載の方法。
- ミニボディーが、PD-L1に特異的なscFvとヒトIgG CH3ドメインとを含む、請求項60記載の方法。
- それを必要とする対象におけるがんを処置する方法であって、
対象に由来するGBMオルガノイド(GBO)と一緒に複数のCAR T細胞を培養する段階、
複数のCAR T細胞から、最高の効力を有するCAR T細胞を選択する段階、および
最高の効力を有するCAR T細胞を対象に投与し、それによって対象におけるがんを処置する段階
を含む、方法。 - 複数のCAR T細胞が、複数のCARを含む複数の改変されたT細胞を含み、各CARが、抗原結合ドメインと、膜貫通ドメインと、細胞内ドメインとを含む、請求項65記載の方法。
- 抗原結合ドメインが、CD19、EGFR、EGFRの複数のアイソフォーム(例えば、野生型EGFR(wtEGFR)、変異型EGFR、EGFRA289V、EGFRA289D、EGFRA289T、EGFRR108K、EGFRR108G、EGFRG598V、EGFRD126Y、EGFRC628F、EGFRR108K/A289V、EGFRR108K/D126Y、EGFRA289V/G598V、EGFRA289V/C628F、およびEGFRバリアントII)、PSMA、PSCA、および任意の腫瘍関連抗原(TAA)からなる群より選択される抗原に結合することが可能である、請求項66記載の方法。
- GBOが対象由来の生検材料から生成される、請求項65記載の方法。
- 最高の効力が、最高度のアポトーシスおよび/または腫瘍細胞死滅として測定される、請求項65記載の方法。
- 追加的な処置を対象に施す段階をさらに含む、請求項65記載の方法。
- 追加的な処置が、免疫チェックポイント阻害(ICB)を含む、請求項66記載の方法。
- ICBが、抗PD-1処置、抗PD-L1処置、抗TIM3処置、および抗CTLA-4処置からなる群より選択される、請求項67記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962833456P | 2019-04-12 | 2019-04-12 | |
US62/833,456 | 2019-04-12 | ||
US201962892343P | 2019-08-27 | 2019-08-27 | |
US62/892,343 | 2019-08-27 | ||
PCT/US2020/027859 WO2020210768A1 (en) | 2019-04-12 | 2020-04-11 | Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022526856A true JP2022526856A (ja) | 2022-05-26 |
JPWO2020210768A5 JPWO2020210768A5 (ja) | 2022-09-30 |
Family
ID=72751475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021560665A Pending JP2022526856A (ja) | 2019-04-12 | 2020-04-11 | 臨床的に意義のあるegfr変異型タンパク質との交差反応性を有する高親和性キメラ抗原受容体(car)を含む、組成物および方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220184129A1 (ja) |
EP (1) | EP3952885A4 (ja) |
JP (1) | JP2022526856A (ja) |
AU (1) | AU2020272074A1 (ja) |
WO (1) | WO2020210768A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3204368A1 (en) * | 2020-12-08 | 2022-06-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-egfr chimeric antigen receptors |
EP4344409A1 (en) * | 2021-07-01 | 2024-04-03 | Duke University | D2c7 egfr and egfr viii bi-specific chimeric antigen receptor constructs and methods of making and using same |
WO2023015300A1 (en) * | 2021-08-06 | 2023-02-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing car t cell efficacy through the engineered secretion of c. perfringens neuraminidase |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
ES2681948T3 (es) * | 2013-03-05 | 2018-09-17 | Baylor College Of Medicine | Células de acoplamiento para inmunoterapia |
EP3623380A1 (en) * | 2013-03-15 | 2020-03-18 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
WO2014201378A1 (en) * | 2013-06-13 | 2014-12-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy |
CA2942101A1 (en) * | 2014-03-21 | 2015-09-24 | Abbvie Inc. | Anti-egfr antibodies and antibody drug conjugates |
KR102110187B1 (ko) * | 2014-05-14 | 2020-05-14 | 카르스젠 테라퓨틱스 리미티드 | 키메라 항원 수용체 단백질을 코딩하는 핵산 및 키메라 항원 수용체 단백질을 발현하는 t 림프구 |
EP3331920A4 (en) * | 2015-08-07 | 2019-04-03 | Seattle Children's Hospital, dba Seattle Children's Research Institute | T CARRIER CARRIER CELLS FOR BISPECIFICATION OF SOLID TUMOR TARGETING |
US20190269727A1 (en) * | 2015-12-28 | 2019-09-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
CN108884459B (zh) * | 2016-04-26 | 2024-04-02 | 科济生物医药(上海)有限公司 | 一种改善免疫应答细胞功能的方法 |
KR20190101979A (ko) * | 2016-12-02 | 2019-09-02 | 유니버시티 오브 써던 캘리포니아 | 합성 면역 수용체 및 이의 사용 방법 |
WO2020114518A1 (zh) * | 2018-12-07 | 2020-06-11 | 科济生物医药(上海)有限公司 | 肿瘤联合免疫治疗 |
-
2020
- 2020-04-11 EP EP20787846.3A patent/EP3952885A4/en active Pending
- 2020-04-11 AU AU2020272074A patent/AU2020272074A1/en active Pending
- 2020-04-11 US US17/602,949 patent/US20220184129A1/en active Pending
- 2020-04-11 JP JP2021560665A patent/JP2022526856A/ja active Pending
- 2020-04-11 WO PCT/US2020/027859 patent/WO2020210768A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020272074A1 (en) | 2021-11-25 |
EP3952885A1 (en) | 2022-02-16 |
EP3952885A4 (en) | 2023-01-18 |
WO2020210768A1 (en) | 2020-10-15 |
US20220184129A1 (en) | 2022-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230416408A1 (en) | Compositions and Methods for Targeting Stromal Cells for the Treatment of Cancer | |
KR102546296B1 (ko) | 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도 | |
JP6991131B2 (ja) | Hiv感染症を処置するためにt細胞を再度方向付ける方法 | |
TW202140530A (zh) | 前列腺特異性膜抗原car及其使用方法 | |
JP2023062132A (ja) | 移植された組織を拒絶反応から保護するための方法 | |
US20220168351A1 (en) | Treatment of a canine cd20 positive disease or condition using a canine cd20-specific chimeric antigen receptor | |
US20220184129A1 (en) | Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins | |
KR20170075792A (ko) | T 세포를 자극 및 증대시키는 조성물 및 방법 | |
US20210324332A1 (en) | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy | |
US20220168407A1 (en) | Use of tumor-independent antigens in immunotherapies | |
US20210322471A1 (en) | In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy | |
US20240131160A1 (en) | Targeting t regulatory cells to islet cells to stall or reverse type 1 diabetes | |
US20240158506A1 (en) | Methods to protect transplanted tissue from rejection | |
US20220088071A1 (en) | A BW6 Specific CAR Designed To Protect Transplanted Tissue From Rejection | |
US20210347845A1 (en) | Compositions and methods for switchable car t cells using surface-bound sortase transpeptidase | |
WO2023091420A2 (en) | Compositions and methods for t cell engineering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220921 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230317 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230531 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240207 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240502 |